Vincere Biosciences, Inc.

Vincere Biosciences, Inc., a Cambridge, Massachusetts-based for-profit biopharmaceutical company, operates as a federal grant recipient developing small-molecule USP30 inhibitors for mitochondrial-dysfunction diseases including acute kidney injury, Parkinson's disease, and cardiac aging. The company holds no federal contracts and no set-aside certifications; all four recent federal awards are National Institutes of Health research grants totaling $3.6 million obligated, and the vendor acts as a prime recipient on 100% of its awards with no federal subcontract footprint.

Vincere's customer base is concentrated entirely within NIH. Three NIH institutes have funded the company's drug-discovery platform: the National Institute of Neurological Disorders and Stroke (two awards), the National Institute of Diabetes and Digestive and Kidney Diseases (one award), and the National Institute on Aging (one award). The most recent award, obligated August 28, 2026, is a $1.297 million NIDDK Project Grant (CFDA 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research) to conduct IND-enabling studies of USP30 inhibitors for acute kidney injury, with performance through May 31, 2028. A prior $1.259 million NINDS award (September 19, 2023, ultimate completion August 31, 2025) supported in vivo evaluation of USP30 inhibitors in Parkinson's disease models; an earlier NIA award (August 15, 2022, ultimate completion July 31, 2023) funded evaluation of USP30 inhibitors in cardiac aging models. Vincere's work across these grants demonstrates potent and selective USP30 inhibition with favorable pharmacokinetic and ADME profiles, advancing multiple molecules toward clinical development across three distinct disease indications.

Activity has been episodic — one award in 2020, one in 2022, one in 2023, one in 2026 — with one award (the current NIDDK grant) carrying an ultimate completion date within the next twenty-four months.